Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms

Julian Lindsay^{1

2}, Carla S Walti^{1

3}, Anna B Halpern^{4

5}, Hu Xie⁴, E Lisa Chung¹, Kelda G Schonhoff⁴, Emily M Huebner¹, Guang-Shing Cheng^{1

4

6}, Louise E Kimball¹, Wendy M Leisenring¹, Matthew Greenwood^{7

8}, Sharon C-A Chen^{2

9}, David C M Kong^{10

11

12}, Monica A Slavin^{2

13

14}, Michael Boeckh^{1

15}, David N Fredricks^{1

15}, Catherine Liu^{1

15}, Steven A Pergam^{1

15}, Roland B Walter^{4

5

16

17}, Joshua A Hill^{1

15}

Affiliations

¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
² National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³ Division of Infectious Diseases and Hospital Epidemiology, Basel University Hospital, Basel, Switzerland.
⁴ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
⁵ Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.
⁶ Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Washington, Seattle, WA.
⁷ Haematology Department, Royal North Shore Hospital, Sydney, NSW, Australia.
⁸ Northern Blood Research Centre, Kolling Institute of Medical Research, The University of Sydney, Sydney, Australia.
⁹ Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, The University of Sydney, Sydney, NSW, Australia.
¹⁰ National Health and Medical Research Council National Centre for Antimicrobial Stewardship at The Peter Doherty Institute for Infections and Immunity, Parkville, VIC, Australia.
¹¹ Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
¹² Pharmacy Department, Grampians Health, Ballarat, VIC, Australia.
¹³ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
¹⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
¹⁵ Division of Allergy & Infectious Diseases, University of Washington, Seattle, WA.
¹⁶ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA.
¹⁷ Department of Epidemiology, University of Washington, Seattle, WA.

PMID: 36790925
PMCID: PMC10362529
DOI: 10.1182/bloodadvances.2022009562

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms

Julian Lindsay et al. Blood Adv. 2023.

. 2023 Jul 11;7(13):3140-3145.

doi: 10.1182/bloodadvances.2022009562.

Authors

Affiliations

¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
² National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³ Division of Infectious Diseases and Hospital Epidemiology, Basel University Hospital, Basel, Switzerland.
⁴ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
⁵ Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.
⁶ Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Washington, Seattle, WA.
⁷ Haematology Department, Royal North Shore Hospital, Sydney, NSW, Australia.
⁸ Northern Blood Research Centre, Kolling Institute of Medical Research, The University of Sydney, Sydney, Australia.
⁹ Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, The University of Sydney, Sydney, NSW, Australia.
¹⁰ National Health and Medical Research Council National Centre for Antimicrobial Stewardship at The Peter Doherty Institute for Infections and Immunity, Parkville, VIC, Australia.
¹¹ Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
¹² Pharmacy Department, Grampians Health, Ballarat, VIC, Australia.
¹³ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
¹⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
¹⁵ Division of Allergy & Infectious Diseases, University of Washington, Seattle, WA.
¹⁶ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA.
¹⁷ Department of Epidemiology, University of Washington, Seattle, WA.

PMID: 36790925
PMCID: PMC10362529
DOI: 10.1182/bloodadvances.2022009562

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.L. has served on advisory boards for Mayne Pharma, Merck Sharp & Dohme (MSD), Amgen, and Bristol Myers Squibb. M.A.S. has sat on advisory boards for Gilead, Pfizer, Merck, F2G, and Takeda, and received research funding from F2G, Gilead, and Merck. M.G. has served on advisory boards for Amgen, Pfizer, Servier, and Jazz Pharmaceuticals and has received trial and research support from Amgen and Servier outside of the submitted work. D.C.M.K. has served on advisory boards for Becton Dickinson Pty Ltd. and MSD and received financial support from MSD and F2G, all unrelated to the current work. S.A.P. receives research support from Global Life Technologies, Inc; participated in research trials with Chimerix Inc., Merck & Co, F2G, Cidara, and Symbio; and participated in a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (U01-AI132004) in which vaccines were provided by Sanofi. M.B. served as a consultant for and received research funding from Gilead Sciences and Merck. A.B.H. served as a consultant for AbbVie and Agios and received research funding from Pfizer, Nohla Therapeutics, Jazz Pharmaceuticals, Imago Pharmaceuticals, Novartis, Bayer, Tolero Pharmaceuticals, Agios Pharmaceuticals, and Gilead. R.B.W. served as a consultant for AbbVie, Amgen, Amphivena, BerGenBio, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Immunogen, and Orum; received research funding from Celgene, Janssen, and Pfizer; and has ownership interests in Amphivena. J.A.H. has received a research grant from Deverra Therapeutics (formerly Nohla Therapeutics) for the support of the work; consulting fees from Karius Inc and Pfizer; and research support from Deverra Therapeutics, Karius, and Merck. The remaining authors declare no competing financial interests.

Figures

**Figure 1.**
**CI of proven/probable IFD at cycle 1 onwards.** CI of proven/probable IFD from cycle 1 (including subsequent cycles) until day 180 or specified end point, for ND CLAG-M vs R/R CLAG-M vs 7 + 3 (A) and CLAG-M vs 7 + 3 with and without M-PPX (B) (shown as PPX D14). Numbers below the curves indicate patients at risk. Death was treated as a competing risk event. P values are from Gray test comparing cohorts.

See this image and copyright information in PMC

References

1. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043–3054. - PubMed
1. Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230. - PubMed
1. Halpern AB, Othus M, Huebner EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32(11):2352–2362. - PMC - PubMed
1. Halpern AB, Othus M, Huebner EM, et al. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica. 2019;104(4):e143–e146. - PMC - PubMed
1. Patzke CL, Duffy AP, Duong VH, et al. Comparison of high-dose cytarabine, mitoxantrone, and pegaspargase (HAM-pegA) to high-dose cytarabine, mitoxantrone, cladribine, and filgrastim (CLAG-M) as first-line salvage cytotoxic chemotherapy for relapsed/refractory acute myeloid leukemia. J Clin Med. 2020;9(2):536. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms

Affiliations

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms

Authors

Affiliations

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical